#United States #New York #Lucid Diagnostics #EsoGuard Test #PAVmed Inc

Lucid Diagnostics Announces New Stock Offering

Lucid Diagnostics Inc., known for its innovative medical solutions targeting cancer prevention, has recently revealed the pricing for its public stock offering. This announcement highlights the company’s ongoing commitment to expanding its operations and enhancing its capabilities in cancer diagnostics.

On April 9, 2025, Lucid Diagnostics set the price at $1.20 per share for 12,500,000 shares in its underwritten public offering. Additionally, the company has granted underwriters a 45-day option to purchase up to 1,875,000 additional shares at the offering price. This stock sale is projected to generate approximately $15 million in gross proceeds, a significant investment that Lucid plans to allocate towards working capital and general corporate purposes.

Why This Offering is Important

The decision to proceed with this public offering comes at a strategic time for Lucid, particularly as the company focuses on patients suffering from gastroesophageal reflux disease (GERD), a condition that increases the risk of esophageal cancer. Lucid is recognized for its EsoGuard® Esophageal DNA Test, which stands out as the first commercially available tool designed to prevent cancer through early detection of precancerous conditions in high-risk patients. Such innovative services showcase the company’s ongoing commitment to combating cancer and improving patient outcomes.

Closing and Underwriter Details

The stock offering is expected to close on or about April 11, 2025, pending customary closing conditions. Notably, Canaccord Genuity LLC is serving as the sole bookrunner, with Maxim Group LLC acting as co-manager for the offering. This coordinated effort by respected financial institutions adds an extra layer of credibility to the offering.

Registration and Compliance

The public offering is being conducted in accordance with a previously declared effective shelf registration statement, bringing transparency and regulatory compliance into the process. Lucid Diagnostics emphasizes that the offering should not be viewed as a solicitation to buy shares in any state or jurisdiction where the offer is illegal or unqualified under local securities laws.

For stakeholders and potential investors, the upcoming prospectus supplement will provide further insights into this offering and its intended use of proceeds. Investors are encouraged to stay informed and review the filings with the Securities and Exchange Commission, available at their website.

Future Prospects

With this financial initiative, Lucid Diagnostics aims to fortify its research and development capabilities. The company is aware of various risks associated with the biotechnology field, including market fluctuations and regulatory challenges. However, this offering reflects Lucid's proactive approach to securing the necessary funding to drive innovation and growth.

As Lucid Diagnostics continues its mission to enhance cancer prevention strategies, each step they take is pivotal in the fight against prevalent diseases. Their focus not only highlights the need for reliable diagnostic tools but also showcases the critical role that public offering plays in funding essential research and product development.

For more information about Lucid Diagnostics and their initiatives against cancer, visit luciddx.com.

• ---

Forward-Looking Statements:
This article contains forward-looking statements, which involve inherent risks and uncertainties that may cause actual results to differ.